Sandra Cuéllar

973 total citations
30 papers, 462 citations indexed

About

Sandra Cuéllar is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sandra Cuéllar has authored 30 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sandra Cuéllar's work include Biosimilars and Bioanalytical Methods (8 papers), Pharmaceutical Economics and Policy (7 papers) and Pharmaceutical studies and practices (6 papers). Sandra Cuéllar is often cited by papers focused on Biosimilars and Bioanalytical Methods (8 papers), Pharmaceutical Economics and Policy (7 papers) and Pharmaceutical studies and practices (6 papers). Sandra Cuéllar collaborates with scholars based in United States, Canada and Singapore. Sandra Cuéllar's co-authors include Stacy S. Shord, Eric M. Tichy, John Spencer Clark, Glen T. Schumock, Linda R. Bressler, James M. Hoffman, Mina Tadrous, Matthew H Rim, Katie J. Suda and Michelle D. Wiest and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Pharmacotherapy.

In The Last Decade

Sandra Cuéllar

29 papers receiving 447 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra Cuéllar United States 13 115 98 75 60 57 30 462
Anthony Louder United States 11 56 0.5× 72 0.7× 69 0.9× 33 0.6× 35 0.6× 17 353
Maxine D. Fisher United States 18 149 1.3× 126 1.3× 59 0.8× 16 0.3× 27 0.5× 52 744
Heather Norman United States 14 32 0.3× 49 0.5× 96 1.3× 68 1.1× 50 0.9× 21 567
Joshua Ray Switzerland 15 90 0.8× 294 3.0× 53 0.7× 53 0.9× 25 0.4× 45 875
Marie‐Blanche Valnet‐Rabier France 13 83 0.7× 27 0.3× 97 1.3× 35 0.6× 43 0.8× 28 478
Weng-Foung Huang Taiwan 16 104 0.9× 48 0.5× 82 1.1× 19 0.3× 58 1.0× 27 568
Neel Shah United States 13 118 1.0× 44 0.4× 53 0.7× 41 0.7× 100 1.8× 38 472
Przemysław Holko Poland 12 63 0.5× 48 0.5× 52 0.7× 18 0.3× 74 1.3× 33 358
Jan Geißler United Kingdom 12 110 1.0× 185 1.9× 92 1.2× 45 0.8× 16 0.3× 48 786
Xiting Cao United States 14 255 2.2× 60 0.6× 105 1.4× 50 0.8× 24 0.4× 45 683

Countries citing papers authored by Sandra Cuéllar

Since Specialization
Citations

This map shows the geographic impact of Sandra Cuéllar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Cuéllar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Cuéllar more than expected).

Fields of papers citing papers by Sandra Cuéllar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Cuéllar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Cuéllar. The network helps show where Sandra Cuéllar may publish in the future.

Co-authorship network of co-authors of Sandra Cuéllar

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Cuéllar. A scholar is included among the top collaborators of Sandra Cuéllar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Cuéllar. Sandra Cuéllar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tichy, Eric M., James M. Hoffman, Mina Tadrous, et al.. (2024). National trends in prescription drug expenditures and projections for 2024. American Journal of Health-System Pharmacy. 81(14). 583–598. 12 indexed citations
3.
Tichy, Eric M., James M. Hoffman, Mina Tadrous, et al.. (2023). National trends in prescription drug expenditures and projections for 2023. American Journal of Health-System Pharmacy. 80(14). 899–913. 31 indexed citations
4.
Cuéllar, Sandra, et al.. (2022). The Current Landscape for METex14 Skipping Mutations in Non–Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology. 13(5). 539–544. 13 indexed citations
5.
Tichy, Eric M., James M. Hoffman, Katie J. Suda, et al.. (2022). National trends in prescription drug expenditures and projections for 2022. American Journal of Health-System Pharmacy. 79(14). 1158–1172. 40 indexed citations
6.
Cuéllar, Sandra, David Chan, Michael T. Huber, et al.. (2021). Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report. JTO Clinical and Research Reports. 2(11). 100241–100241. 1 indexed citations
7.
Cuéllar, Sandra. (2020). Integrating trastuzumab biosimilars and HER2-directed therapies into HER2-positive breast cancer management. The American Journal of Managed Care. 26(Suppl 2). S32–S40. 19 indexed citations
8.
Tichy, Eric M., Glen T. Schumock, James M. Hoffman, et al.. (2020). National trends in prescription drug expenditures and projections for 2020. American Journal of Health-System Pharmacy. 77(15). 1213–1230. 38 indexed citations
9.
Cuéllar, Sandra, Ali McBride, & Patrick J. Medina. (2019). Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice. American Journal of Health-System Pharmacy. 76(21). 1725–1738. 11 indexed citations
10.
Schumock, Glen T., JoAnn Stubbings, James M. Hoffman, et al.. (2019). National trends in prescription drug expenditures and projections for 2019. American Journal of Health-System Pharmacy. 76(15). 1105–1121. 28 indexed citations
11.
Arco, Débora Álvarez-del, Maria Jesús Pérez‐Elías, José Ramón Blanco, et al.. (2018). Role of HIV in the desire of procreation and motherhood in women living with HIV in Spain: a qualitative approach. BMC Women s Health. 18(1). 24–24. 5 indexed citations
12.
Hsu, Grace, Stephanie Y. Crawford, Sandra Cuéllar, et al.. (2017). Design of Customized Mobile Application for Patient Adherence to Oral Anticancer Medications Utilizing User-Centered Design. PubMed. 41(1). e3–e3. 6 indexed citations
13.
Fleming, Patrick, et al.. (2017). Pharmacological management of anticancer agent extravasation: A single institutional guideline. Journal of Oncology Pharmacy Practice. 24(2). 129–138. 13 indexed citations
14.
Anderson, Jennifer M. & Sandra Cuéllar. (2016). Updates in the Use of the mTOR Inhibitor Everolimus in Advanced Breast Cancer. 2016(2). 1–6. 1 indexed citations
15.
Seddon, Amanda N., et al.. (2013). The life, death, and attempted rebirth of bevacizumab in breast cancer. Journal of Oncology Pharmacy Practice. 20(6). 433–444. 3 indexed citations
16.
Cuéllar, Sandra, et al.. (2012). Bevacizumab-Induced Oral Mucositis in Background of Cutaneous Plaque-Type Psoriasis. Annals of Pharmacotherapy. 46(11). e32–e32. 4 indexed citations
17.
Shord, Stacy S., et al.. (2010). Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia. Journal of Oncology Pharmacy Practice. 17(4). 360–365. 8 indexed citations
18.
Shord, Stacy S., et al.. (2009). Understanding and managing the possible adverse effects associated with bevacizumab. American Journal of Health-System Pharmacy. 66(11). 999–1013. 89 indexed citations
19.
Shord, Stacy S. & Sandra Cuéllar. (2008). Chemotherapy-induced anemia at an urban academic medical center: Iron studies and supplementation. Journal of the American Pharmacists Association. 48(4). 487–493. 5 indexed citations
20.
Shord, Stacy S., J. Michael Hamilton, & Sandra Cuéllar. (2008). Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia. Journal of Oncology Pharmacy Practice. 14(1). 5–22. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anthony Louder Breakdown of academic impact, for papers by Maxine D. Fisher Breakdown of academic impact, for papers by Heather Norman Breakdown of academic impact, for papers by Joshua Ray Breakdown of academic impact, for papers by Marie‐Blanche Valnet‐Rabier Breakdown of academic impact, for papers by Weng-Foung Huang Breakdown of academic impact, for papers by Neel Shah Breakdown of academic impact, for papers by Przemysław Holko Breakdown of academic impact, for papers by Jan Geißler Breakdown of academic impact, for papers by Xiting Cao
Rankless by CCL
2026